title: Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled JUNCTURE trial.
abstract: BACKGROUND
  User satisfaction is an important factor associated with treatment adherence in chronic diseases including moderate-to-severe psoriasis.
  
  
  OBJECTIVE
  To evaluate the efficacy, safety and patient acceptability of 300 and 150 mg secukinumab - a fully human anti-interleukin-17A monoclonal antibody that has demonstrated efficacy in the treatment of patients with moderate-to-severe plaque psoriasis - self-administered by autoinjection.
  
  
  METHODS
  Patients with moderate-to-severe plaque psoriasis were randomized to secukinumab 300 mg, secukinumab 150 mg or placebo self-administered by autoinjection at baseline, Weeks 1, 2 and 3 and then every 4 weeks from Week 4 to Week 48. Efficacy responses [≥75/90/100% improvement in Psoriasis Area and Severity Index (PASI 75/90/100) and clear/almost clear skin by Investigator's Global Assessment 2011 modified version (IGA mod 2011 0/1)] were measured at Week 52. Patient-reported usability of the autoinjector was evaluated by the self-injection assessment questionnaire to Week 48.
  
  
  RESULTS
  At Week 52 with secukinumab 300 mg, PASI 75/90/100 and IGA mod 2011 0/1 responses were achieved by 81.4/64.1/38.8% and 69.6% of patients, respectively, by multiple imputation. At Week 52 with secukinumab 150 mg, PASI 75/90/100 and IGA mod 2011 0/1 responses were achieved by 75.2/57.4/33.1% and 60.2% of patients, respectively, by multiple imputation. Patient-assessed acceptability of the autoinjector remained high to Week 48. The proportion of patients experiencing adverse events was greater with secukinumab 300 mg (88.6%) than with secukinumab 150 mg (78.7%).
  
  
  CONCLUSIONS
  Self-administration of secukinumab using an autoinjector was associated with robust and sustained efficacy, a good safety profile and high acceptability.
authors.affiliation: Department of Dermatology, University Hospital of Nice, Nice, France.
authors.forename: J-P
authors.initials: JP
authors.lastname: Lacour
authors.affiliation: Department of Dermatology, Paul Sabatier University, Toulouse, France.
authors.forename: C
authors.initials: C
authors.lastname: Paul
authors.affiliation: Alliance Dermatology and MOHS Center, Phoenix, AZ, USA.
authors.forename: S
authors.initials: S
authors.lastname: Jazayeri
authors.affiliation: Novartis Pharma AG, Basel, Switzerland.
authors.forename: P
authors.initials: P
authors.lastname: Papanastasiou
authors.affiliation: Stanford University, Stanford, CA, USA.
authors.forename: C
authors.initials: C
authors.lastname: Xu
authors.affiliation: Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
authors.forename: J
authors.initials: J
authors.lastname: Nyirady
authors.affiliation: Novartis Pharma AG, Basel, Switzerland.
authors.forename: T
authors.initials: T
authors.lastname: Fox
authors.affiliation: Novartis Pharma AG, Basel, Switzerland.
authors.forename: C
authors.initials: C
authors.lastname: Papavassilis
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D004311:Double-Blind Method; D006801:Humans; D010919:Placebos; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology; D012646:Self Administration; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D010919:Placebos; C555450:secukinumab